Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients with DLBCL

Trial Identifier: D8227C00002
Sponsor: AstraZeneca
Start Date: July 2024
Primary Completion Date: March 2029
Study Completion Date: March 2029
Condition: Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BR Barretos, BR, 14784-400
BR Belo Horizonte, BR, 30150-221
BR Brasilia, BR, 70200-730
BR Brasilia, BR, 70840-901
BR Brasilia, BR, 70390-700
BR Campinas, BR, 13060-803
BR Curitiba, BR, 81520-060
BR Florianópolis, BR, 88034-000
BR Florianópolis, BR, 88020-210
BR Goiania, BR, 74605-020
BR Natal, BR, 59075-740
BR Porto Alegre, BR, 90035-003
BR Porto Alegre, BR, 90880-480
BR Recife, BR, 50070-480
BR Ribeirão Preto, BR, 14048-900
BR Rio de Janeiro, BR, 20231-050
BR São José do Rio Preto, BR, 15090-000
BR Sao Luis, BR, 65060-645
BR São Paulo, BR, 05652-900
BR São Paulo, BR, 1323000
BR São Paulo, BR, 01409-02
BR São Paulo, BR, 08270-070
BR São Paulo, BR, 01229-010
BR Sorocaba, BR, 18030-005
KR Busan, KR, 47392
KR Busan, KR, 49241
KR Daegu, KR, 42601
KR Gyeongsangnam-do, KR, 52727
KR Incheon, KR, 405-760
KR Jeonju-si, KR, 54907
KR Seo-gu, KR, 49201
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 06591
KR Seoul, KR, 06351
KR Seoul, KR, 07985
KR Suwon-si, KR, 16499
KR Ulsan, KR, 44033
US, CA La Jolla, CA, US, 92093
US, CA Orange, CA, US, 92868
US, FL Jacksonville, FL, US, 32256
US, IA Des Moines, IA, US, 50309
US, MD Beltsville, MD, US, 20705
US, MD Towson, MD, US, 21204
US, MI Detroit, MI, US, 48202
US, PR San Juan, PR, US, 00917
US, TX Lubbock, TX, US, 79410
US, WA Olympia, WA, US, 98506
US, WA Tacoma, WA, US, 98405